Elevations of Cardiac Troponin in Patients Receiving Immune Checkpoint Inhibitors DOI Creative Commons
Pieter F. van den Berg, Valentina Bračun,

Michel Noordman

et al.

JACC Advances, Journal Year: 2024, Volume and Issue: 3(12), P. 101375 - 101375

Published: Nov. 7, 2024

Immune checkpoint inhibitors (ICIs) are increasingly used in the treatment of cancer. However, immune-related adverse events prevalent patients receiving ICI therapy. A serious event is ICI-myocarditis, which complex to diagnose given that significance early symptoms and biomarker trajectories, such as high-sensitivity troponin T (hs-TnT) unclear.

Language: Английский

Immune Checkpoint Inhibitor–Related Myocarditis With or Without Concomitant Myopathy DOI Creative Commons

Osnat Itzhaki Ben Zadok,

Méabh O’Hare, Anju Nohria

et al.

JACC CardioOncology, Journal Year: 2025, Volume and Issue: unknown

Published: March 1, 2025

Language: Английский

Citations

1
Diagnostic Value of Rock2 Protein in Immune Checkpoint Inhibitors-Associated Myocarditis DOI

Caie Li,

Yucheng Jin, Ma J

et al.

Published: Jan. 1, 2025

Download This Paper Open PDF in Browser Add to My Library Share: Permalink Using these links will ensure access this page indefinitely Copy URL DOI

Language: Английский

Citations

0
Characteristics, Incidence, and Management of Immune Checkpoint Inhibitors Related Cardiovascular Adverse Events in Real-World Practice-A Retrospective Study in Chinese Han Population DOI Creative Commons
R. Wang,

Yin Chen,

Yaling Lou

et al.

Therapeutics and Clinical Risk Management, Journal Year: 2025, Volume and Issue: Volume 21, P. 125 - 135

Published: Feb. 1, 2025

This study aimed to elaborate on the incidence, clinical features, and management of immune checkpoint inhibitors (ICIs) related cardiovascular adverse events (CVAEs) in real-world practice. We performed a retrospective chart review patients receiving at least one dose ICI therapy Chinese tertiary hospital from March 2020 2021. CVAEs were identified through assessment Naranjo algorithm. The outcomes monitored over median follow-up duration 8 months. Among included 203 patients, 4.4% (9/203) developed CVAEs, including heart failure (n = 3), arrhythmia 2), myocarditis pericardial disease with proportion (6/9) tending be severe (grade 3 or grade 4). more common older (mean age: 73.6 ± 9.2 years) those hypertension (p 0.02) 0.01). Adherence American Society Clinical Oncology (ASCO) guidelines for managing was low (44%), most cases showing partial resolution by last follow-up. reported that incidence ICI-related institution higher than some prior studies. is found suboptimal practice highlighted as needed improvement.

Language: Английский

Citations

0
Diagnostic value of ROCK2 protein in immune checkpoint inhibitors-associated myocarditis DOI

Caie Li,

Yucheng Jin, Ma J

et al.

International Journal of Cardiology, Journal Year: 2025, Volume and Issue: 427, P. 133104 - 133104

Published: March 2, 2025

Language: Английский

Citations

0
Multimodality Imaging and Immune‐Related Adverse Events During Immune Checkpoint Inhibitors Treatment: Where Do We Stand? DOI

Stephanie Crosio,

Giorgio Treglia, Martina Imbimbo

et al.

Echocardiography, Journal Year: 2025, Volume and Issue: 42(3)

Published: March 1, 2025

Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy, significantly improving survival across various malignancies. However, these therapies are associated with types of immune-related adverse events (irAEs), including cardiotoxicity, a spectrum rare but potentially life-threatening complications impacting morbidity and mortality. Cardiovascular imaging has become key in cardio-oncology, providing essential diagnostic tools for early detection monitoring. This review synthesizes current evidence underlines the pivotal role tailored strategies managing ICI-induced cardiotoxicity. By bridging knowledge gap, it aims to provide targetable insights optimize clinical management patients undergoing immunotherapy.

Language: Английский

Citations

0
Immune Checkpoint Inhibitor-Related Myocarditis, Myopathy, and More DOI Creative Commons
Jafar Al‐Mondhiry, Ana Barac

JACC CardioOncology, Journal Year: 2025, Volume and Issue: 7(3), P. 265 - 267

Published: April 1, 2025

Language: Английский

Citations

0
Multimodal Imaging of Immune Checkpoint Inhibitor Myocarditis DOI Open Access
Shreyans Patel, Kartikeya Dave, Mario J. García

et al.

Journal of Clinical Medicine, Journal Year: 2025, Volume and Issue: 14(8), P. 2850 - 2850

Published: April 21, 2025

Immune checkpoint inhibitors (ICIs) have dramatically changed the landscape of cancer treatment and are increasingly used either as monotherapy or in combination with other ICIs, chemotherapy, molecularly targeted agents. ICI myocarditis is a rare but potentially fatal irAE associated use characterized by T-cell mediated cardiomyocyte death. Diagnosing can be intricate its atypical presentations. Multimodal imaging plays crucial role diagnosis risk stratification myocarditis. Current management strategies for include corticosteroids immunosuppressants. Multidisciplinary collaboration vital these cases—combining oncology expertise cardiology insights.

Language: Английский

Citations

0
Elevations of Cardiac Troponin in Patients Receiving Immune Checkpoint Inhibitors DOI Creative Commons
Pieter F. van den Berg, Valentina Bračun,

Michel Noordman

et al.

JACC Advances, Journal Year: 2024, Volume and Issue: 3(12), P. 101375 - 101375

Published: Nov. 7, 2024

Immune checkpoint inhibitors (ICIs) are increasingly used in the treatment of cancer. However, immune-related adverse events prevalent patients receiving ICI therapy. A serious event is ICI-myocarditis, which complex to diagnose given that significance early symptoms and biomarker trajectories, such as high-sensitivity troponin T (hs-TnT) unclear.

Language: Английский

Citations

1